GlaxoSmithKline (GSK) Pharma has announced a collaboration agreement with Japan based Astellas Pharma Inc. for exclusive rights for the latter's injectible anti-fungal agent Micafungin (brand name Mycamine) in the Indian market.
Micafungin, an original research product of Astellas was initially approved by Japanese Agency in 2002, by the US FDA in 2005 followed by other countries.
The details can be read here.
No comments:
Post a Comment